https://scholars.lib.ntu.edu.tw/handle/123456789/496108
標題: | Rosiglitazone is not associated with an increased risk of bladder cancer | 作者: | CHIN-HSIAO TSENG | 公開日期: | 2013 | 卷: | 37 | 期: | 4 | 起(迄)頁: | 385-389 | 來源出版物: | Cancer Epidemiology | 摘要: | Background: Whether rosiglitazone may increase bladder cancer risk has not been extensively investigated. Methods: The reimbursement databases of all Taiwanese diabetic patients under oral anti-diabetic agents or insulin from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and a total of 885,236 patients with type 2 diabetes were followed up for bladder cancer incidence till end of 2009. Incidences for ever-users, never-users and subgroups of rosiglitazone exposure (using tertile cutoffs of time since starting rosiglitazone, duration of therapy and cumulative dose) were calculated and hazard ratios estimated by Cox regression. Results: There were 102,926 ever-users and 782,310 never-users, respective numbers of incident bladder cancer 356 (0.35%) and 2753 (0.35%), and respective incidence 98.3 and 101.6 per 100,000 person-years. The overall hazard ratios (95% confidence intervals) did not show significant association in unadjusted model [0.969 (0.867, 1.082)] and models adjusted for age and sex [0.983 (0.880, 1.098)] or all covariates [0.980 (0.870, 1.104)]. Neither the P values for the hazard ratios for the different categories of the dose-responsive parameters, nor their P-trends were significant. Conclusions: Rosiglitazone does not increase the risk of bladder cancer. ? 2013 Elsevier Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878931167&doi=10.1016%2fj.canep.2013.03.013&partnerID=40&md5=ba029320bfe5b490b2f4fe318d164d70 https://scholars.lib.ntu.edu.tw/handle/123456789/496108 |
ISSN: | 1877-7821 | DOI: | 10.1016/j.canep.2013.03.013 | SDG/關鍵字: | acarbose; angiotensin receptor antagonist; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; fibric acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; meglitinide; metformin; nonsteroid antiinflammatory agent; oral antidiabetic agent; rosiglitazone; sulfonylurea; adult; aged; article; bladder cancer; cancer incidence; cancer risk; controlled study; diabetic patient; dose response; female; human; major clinical study; male; non insulin dependent diabetes mellitus; priority journal; Taiwan; treatment duration; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Taiwan; Thiazolidinediones; Time Factors; Urinary Bladder Neoplasms |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。